Alnylam Pharmaceuticals

News

Pinky promise made by stone statue hands

Alnylam bets on Tenaya RNAi tech, and other licensing news

This week's round-up of pharma licensing deals features alliances involving Tenaya Therapeutics, Sino Bio, Antengene, and A2A Pharma.

News

Alnylam's ATTR cardiomyopathy drug backed for NHS use

Patients with ATTR-CM in England and Wales will soon have a new treatment option, after NICE backed use of Alnylam's three-month injectable Amvuttra.

News

Regeneron preps filings for myasthenia gravis drug

Regeneron could be just a few months away from filing for a myasthenia gravis drug that can be dosed just once every three months.

News

Alnylam joins three-way contest in ATTR cardiomyopathy

Alnylam has claimed FDA approval for Amvuttra in ATTR cardiomyopathy, allowing it to compete with rival therapies from Pfizer and BridgeBio.

News

EU clears AZ, Ionis' Wainzua for ATTR polyneuropathy

AstraZeneca and Ionis add an EU green light to earlier approvals in the US and UK for ATTR polyneuropathy drug Wainzua, a potential blockbuster.

News

11 blockbuster drugs to look out for in 2025

Clarivate has revealed 11 drugs due to launch in 2025 that could top $1 billion in annual sales or be clinical 'game changers' in the next five years.

Alnylam bets on Tenaya RNAi tech, and other licensing news

Alnylam's ATTR cardiomyopathy drug backed for NHS use

Regeneron preps filings for myasthenia gravis drug

Alnylam joins three-way contest in ATTR cardiomyopathy

EU clears AZ, Ionis' Wainzua for ATTR polyneuropathy

11 blockbuster drugs to look out for in 2025

UK's Mission divests kidney drug to Dimerix for $292m

Discover a new era of healthcare panel engagement: Grounded ...

Alnylam Pharmaceuticals

Editor's Picks